Pharmaceutical Corruption News Stories

Excerpts of Key Pharmaceutical Corruption News Stories in Major Media

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

New rules require drugmakers to be clearer and more direct when explaining their medications' risks and side effects. The [new] guidelines ... are designed to do away with industry practices that downplay or distract viewers from risk information. But while regulators were drafting them, a new trend emerged: Thousands of pharma influencers pushing drugs online with little oversight. A new bill in Congress would compel the FDA to more aggressively police such promotions on social media platforms. "Some people become very attached to social media influencers and ascribe to them credibility that, in some cases, they don't deserve," said Tony Cox ... at Indiana University. Still, TV remains the industry's primary advertising format, with over $4 billion spent in the past year. Even so, many companies are looking beyond TV and expanding into social media. They often partner with patient influencers who post about managing their conditions, new treatments or navigating the health system. Advertising executives say companies like the format because it's cheaper than TV and consumers generally feel influencers are more trustworthy than companies. "The power of social media and the deluge of misleading promotions has meant too many young people are receiving medical advice from influencers instead of their health care professional," Sens. Dick Durbin of Illinois and Mike Braun of Indiana wrote the FDA in a February letter.

Note: Prescription drug advertising is only legal in the US and New Zealand. Read more about the influencers who are paid to promote pharmaceuticals on social media. For more along these lines, read our concise summaries of news articles on Big Pharma profiteering and media manipulation.

U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co, may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters. The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning. By 2019, thousands of reports of neuropsychiatric episodes, including dozens of suicides, in patients prescribed the drug had piled up on internet forums and in the U.S. Food and Drug Administration's tracking system. Such "adverse event" reports do not prove a causal link between a medicine and a side effect, but are used by the FDA to determine whether more study of a drug's risks are warranted. The reports and new scientific research led the FDA in 2020 to add a "black box" warning to the montelukast prescribing label, flagging serious mental health risks like suicidal thinking or actions. The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone. When the FDA added the black box, it cited research from Julia Marschallinger and Ludwig Aigner. The two scientists told Reuters ... the new data showed significant quantities of montelukast present in the brain. The receptors involved play a role in governing mood, impulse control, cognition and sleep, among other functions, they said.

Note: Reuters reported that the FDA received more than 80 reports of suicides in people taking the medicine. Learn more about how US courts protected Merck from lawsuits regarding Singulair. For more along these lines, explore concise summaries of news articles on mental health and Big Pharma profiteering from reliable major media sources.

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing brain tumors, a new lawsuit alleged. "For several decades the manufacturers and sellers of Depo-Provera and its authorized generic and generic analogues" had a responsibility to investigate whether the medication could contribute to the growth of brain tumors, according to the complaint filed Monday in the US District Court for the Central District of California. Plaintiff Taylor Devorak alleged that researchers have found Depo-Provera and similar progesterone medications have been linked to a greater incidence of brain tumors called intracranial meningioma. She's seeking damages on her failure-to-warn, defective design, negligence, misrepresentation, and breach of warranty claims against the pharmaceutical giant. Devorak's complaint comes in the wake of a handful of substantially similar lawsuits filed in other federal courts in California and Indiana in recent weeks. The American label for Depo-Provera "still makes no mention of the increased risk to patients of developing intracranial meningiomas," even though the EU and UK now list meningioma under the medication's warning section, Devorak's complaint said. Devorak cited a 2024 study published in the British Medical Journal that said prolonged use of medroxyprogesterone acetate medications like Depo-Provera were found to significantly increase the risk of developing intracranial meningioma.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The controversy over the decision by the Food and Drug Administration (FDA) in late 2004 to require a boxed warning on antidepressants regarding the risk of suicidality in children and adolescents reached a crescendo in 2007 with the publication of a study that presented two ... graphs. One showed a steady increase in antidepressant prescribing to U.S. adolescents, with a notable downtick in the last year of the series; the other showed a steady decrease in suicide rates among U.S. adolescents, with a notable uptick at the end. The prescription downtick occurred in 2005, whereas the suicide uptick had occurred in 2004. Adolescent suicide rates actually decreased for several years beginning in 2005. Despite the admitted error, the report was never retracted and is still widely cited. Ecological studies that examine geographic variability in antidepressant use often show an inverse relationship with suicide rates, but I believe that these results can best be explained by confounding. The same socioeconomic factors that promote greater availability and use of many prescription drugs (including antidepressants) also lower suicide rates among even the substantial majority of the population that does not take antidepressants. For example, one study associated the introduction of leukotriene-modifying agents for asthma and allergic rhinitis with a 3% decrease in suicides in the entire population (even though the drugs are used by only 1% of the population).

Note: For more along these lines, see concise summaries of deeply revealing news articles on mental health and Big Pharma from reliable major media sources.

AstraZeneca is being sued by a woman who claims she was disabled by the company's Covid-19 vaccine. Brianne Dressen said she was "the picture of good health" when getting the AstraZeneca Covid vaccine in 2020 at the age of 39 through a Salt Lake County, Utah, clinical trial. In the hours that followed, her arm began to tingle and the feeling spread up to her shoulder, then to her opposite arm. Later, other symptoms followed, including blurred vision, a headache, ringing ears, and vomiting. In 2021, National Institutes of Health neurologists diagnosed her with "post vaccine neuropathy." Dressen is the co-chair of React19, an interest group for people alleging injury from Covid-19 vaccines. Now, she's suing AstraZeneca over medical expenses and more, arguing she's still disabled and unable to work and carry on with many activities as she once had. The lawsuit, which accuses AstraZeneca of breaching contractual obligations, comes days after AstraZeneca pulled its Covid-19 vaccine off the market. AstraZeneca has said it was doing so due to a lack of demand and not for safety reasons. The vaccine, however, has faced concerns over its efficacy and safety. As of April 1, over 10,000 claims alleging injury or death from a Covid-19 shot have been filed with the Countermeasures Injury Compensation Program, according to the HHS. In a separate lawsuit, Dressen's React19 and people alleging vaccine injuries are suing the HHS over the program.

Note: People injured by AstraZeneca's vaccine were censored on social media when they tried to talk about their experiences. While mainstream narratives emphasize how rare these injuries are, the numbers speak for themselves. The Vaccine Adverse Event Reporting System (VAERS) is a voluntary government reporting system that only captures a portion of the actual injuries. Vaccine adverse event numbers are made publicly available, and currently show 38,068 COVID Vaccine Reported Deaths and 1,652,230 COVID Vaccine Adverse Event Reports.

An influential doctor and advocate of adolescent gender treatments said she had not published a long-awaited study of puberty-blocking drugs because of the charged American political environment. The doctor, Johanna Olson-Kennedy, began the study in 2015 as part of a broader, multimillion-dollar federal project on transgender youth. She and colleagues recruited 95 children from across the country and gave them puberty blockers, which stave off the permanent physical changes – like breasts or a deepening voice – that could exacerbate their gender distress, known as dysphoria. The researchers followed the children for two years to see if the treatments improved their mental health. An older Dutch study had found that puberty blockers improved well-being, results that inspired clinics around the world to regularly prescribe the medications as part of what is now called gender-affirming care. But the American trial did not find a similar trend. Puberty blockers did not lead to mental health improvements, she said. In the nine years since the study was funded ... and as medical care for this small group of adolescents became a searing issue in American politics, Dr. Olson-Kennedy's team has not published the data. Asked why, she said the findings might fuel the kind of political attacks that have led to bans of the youth gender treatments in more than 20 states, one of which will soon be considered by the Supreme Court. "I do not want our work to be weaponized," she said.

Note: We believe that everyone has a right to exist and express themselves the way they want. Yet we value the health of all beings and the importance of informed choice when it comes to any potentially life-changing medical procedure. For more along these lines, explore summaries of revealing news articles on transgender medicine from reliable major media sources.

Drug ads have been ubiquitous on TV since the late 1990s and have spilled onto the internet and social media. The United States and New Zealand are the only countries that legally allow direct-to-consumer pharmaceutical advertising. Manufacturers have spent more than $1 billion a month on ads in recent years. Last year, three of the top five spenders on TV advertising were drug companies. A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. "I worry that direct-to-consumer advertising can be used to drive demand for marginally effective drugs or for drugs with more affordable or more cost-effective alternatives," the study's author, Michael DiStefano ... said. Indeed, more than 50% of what Medicare spent on drugs from 2016 through 2018 was for drugs that were advertised. The government has, in recent years, tried to ensure that prescription-drug advertising gives a more accurate and easily understood picture of benefits and harms. But the results have been disappointing. When President Donald Trump's administration tried to get drugmakers to list the price of any treatments costing over $35 on TV ads, for example, the industry took it to federal court, saying the mandate violated drugmakers' First Amendment rights. Big Pharma won. With a bit of commonsense, truth-in-advertising enforcement, many of the ads would disappear.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The pharmaceutical industry, as a whole and by its nature, is conflicted and significantly driven by the mighty dollar, rather than altruism. A 2020 peer-reviewed article published in the Journal of the American Medical Association outlines the extent of the problem. The group studied both the type of illegal activity and financial penalties imposed on pharma companies between the years 2003 and 2016. Of the companies studied, 85 percent (22 of 26) had received financial penalties for illegal activities with a total combined dollar value of $33 billion. The illegal activities included manufacturing and distributing adulterated drugs, misleading marketing, failure to disclose negative information about a product (i.e. significant side effects including death), bribery to foreign officials, fraudulently delaying market entry of competitors, pricing and financial violations, and kickbacks. The highest penalties were awarded to Schering-Plough, GlaxoSmithKline (GSK), Allergan, and Wyeth. The biggest overall fines have been paid by GSK (almost $10 billion), Pfizer ($2.9 billion), Johnson & Johnson ($2.6 billion), and other familiar names including AstraZeneca, Novartis, Merck, Eli Lilly, Schering-Plough, Sanofi Aventis, and Wyeth. Five US states – Texas, Kansas, Mississippi, Louisiana, and Utah – are taking Pfizer to court for withholding information, and misleading and deceiving the public through statements made in marketing its Covid-19 injection.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Justice Department investigators are scrutinizing the healthcare industry's use of AI embedded in patient records that prompts doctors to recommend treatments. Prosecutors have started subpoenaing pharmaceuticals and digital health companies to learn more about generative technology's role in facilitating anti-kickback and false claims violations, said three sources familiar with the matter.. Two of the sources–speaking anonymously to discuss ongoing investigations–said DOJ attorneys are asking general questions suggesting they still may be formulating a strategy. "I have seen" civil investigative demands "that ask questions about algorithms and prompts that are being built into EMR systems that may be resulting in care that is either in excess of what would have otherwise been rendered, or may be medically unnecessary," said Jaime Jones, who co-leads the healthcare practice at Sidley Austin. DOJ attorneys want "to see what the result is of those tools being built into the system." The probes bring fresh relevance to a pair of 2020 criminal settlements with Purdue Pharma and its digital records contractor, Practice Fusion, over their collusion to design automated pop-up alerts pushing doctors to prescribe addictive painkillers. The kickback scheme ... led to a $145 million penalty for Practice Fusion. Marketers from Purdue ... worked in tandem with Practice Fusion to build clinical decision alerts relying on algorithms.

Note: Read how the US opioid industry operated like a drug cartel. For more along these lines, see concise summaries of deeply revealing news articles on AI and Big Pharma corruption from reliable major media sources.

In December of 2002, Sharyl Attkisson, an Emmy-winning investigative reporter for CBS News, had an unsettling interview with smallpox expert Jonathan Tucker. In a post-9/11 world, with fears of terrorists using a long-eradicated disease like smallpox as a bioweapon, the US was preparing to bring back the smallpox inoculation program. But to Tucker, the very idea was "agonizing," writes Attkisson. Why? Because it involved "weighing the risk of a possible terrorist use of smallpox ... against the known risks of the vaccine," Tucker told the author. "A ‘toxic' vaccine?" She writes. "Didn't the smallpox vaccine save the world?" But as she soon discovered, it had serious side effects, including a surprisingly high possibility of death. Attkisson witnessed firsthand how deadly the vaccine could be in April of 2003, when a colleague at NBC, journalist David Bloom, died from deep vein thrombosis while on assignment in Iraq. He'd also recently been vaccinated for smallpox, and ... thrombosis was a possible side effect of the inoculation. The majority of scientific studies are funded and even dictated by drug companies. "Studies that could stand to truly solve our most consequential health problems aren't done if they don't ultimately advance a profitable pill or injection," Attkisson writes. "These aren't necessarily drugs designed to make us well, but ones we'll ‘need' for life," writes Attkisson. Some [drug companies] hire "ghostwriters" to author studies promoting a new drug, exaggerating benefits and downplaying risks, and then paying a doctor or medical expert to sign their name to it. "We exist largely in an artificial reality brought to you by the makers of the latest pill or injection," she writes. "It's a reality where invisible forces work daily to hype fears about certain illnesses, and exaggerate the supposed benefits of treatments and cures."

Note: Top leaders in the field of medicine and science have spoken out about the rampant corruption and conflicts of interest in those industries. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

[Don] Poldermans was a prolific medical researcher at Erasmus Medical Center in the Netherlands, where he analyzed the standards of care for cardiac events after surgery, publishing a series of definitive studies from 1999 until the early 2010s. One crucial question he studied: Should you give patients a beta blocker, which lowers blood pressure, before certain surgeries? Poldermans's research said yes. European medical guidelines (and to a lesser extent US guidelines) recommended it accordingly. The problem? Poldermans's data was reportedly fake. A 2012 inquiry by Erasmus Medical School, his employer, into allegations of misconduct found that he "used patient data without written permission, used fictitious data and ... submitted to conferences [reports] which included knowingly unreliable data." Poldermans admitted the allegations and apologized. After the revelations, a new meta-analysis was published in 2014, evaluating whether to use beta blockers before non-cardiac surgery. It found that a course of beta blockers made it 27 percent more likely that someone would die within 30 days of their surgery. Millions of surgeries were conducted across the US and Europe during the years from 2009 to 2013 when those misguided guidelines were in place. One provocative analysis ... estimated that there were 800,000 deaths compared to if the best practices had been established five years sooner.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in science and in Big Pharma from reliable major media sources.

What if your entire economy was based on one product? For all intents and purposes, Denmark quite literally runs on Ozempic, a diabetes medication that is now widely used by consumers to lose weight. Worldwide sales have increased by over 60% in the past year alone. In the United States, which is one of its largest markets, prescriptions for Ozempic and similar drugs quadrupled between 2020 and 2022. At the end of 2023, Novo became the largest company in Europe. And its rise has eclipsed the Danish economy, creating a lot of value on the one hand, but an imbalanced economy on the other. You might have heard of "petrostates," countries where fossil fuel extraction dominates the economy. By that measure, you might call Denmark a pharmastate, because Novo now dominates the Danish economy. Nearly 1 out of every 5 Danish jobs created last year was at Novo. And that's just directly. If you also include the jobs that Novo has created indirectly – like, for example, at its suppliers, or from all the newly wealthy Novo employees spending their money at shops and restaurants – nearly half of all private-sector nonfarm jobs created in Denmark can be traced back to Novo. Novo Nordisk's meteoric trajectory raises a question about economic growth that's much bigger than just Denmark: Namely, what are the risks of having one giant company driving your entire economy? And crucially, what happens if that company's fortunes take a turn for the worse?

Note: The makers of these weight-loss drugs could be hit with over 10,000 lawsuits over severe adverse events from these drugs. It is now estimated that 1 in 8 adults in the US have taken Ozempic or another weight-loss drug. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering from reliable major media sources.

During his final three years at the US Food and Drug Administration the physician scientist Doran Fink's work focused on reviewing covid-19 vaccines. But a decade after joining the agency Fink had accepted a job with Moderna, the covid vaccine manufacturer. As he left for the private sector, the FDA's ethics programme staff emailed him guidelines on post-employment restrictions, "tailored to your situation." The email, obtained by The BMJ under a freedom of information request, explained that, although US law prohibits a variety of types of lobbying contact, "they do not prohibit the former employee from other activities, including working ‘behind the scenes.'" The legal ability to work "behind the scenes" is enshrined in federal regulations and highlights a "critical, critical loophole" in US revolving door policy. Craig Holman, a government affairs lobbyist for the organisation Public Citizen, told The BMJ that the rules forbid various forms of direct lobbying contact but permit lobbying activity that is indirect. "So, people will leave government service and can immediately start doing influence peddling and lobbying," Holman explained. "They can even run a lobbying campaign, as long as they don't actually pick up the telephone and make the contact with their former officials." A majority of former FDA reviewers take up jobs in industry. Since 2000 every FDA commissioner, the agency's highest position, has gone on to work for industry.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma from reliable major media sources.

A Supreme Court ruling against the opioid company Purdue Pharma ... substantially raised the bar for executives and owners trying to shield their wealth. Johnson & Johnson, Boy Scouts of America and Rite Aid are among the entities trying to handle a vast number of lawsuits in bankruptcy court, seeking to resolve all claims in a single settlement. These proceedings have echoes of the Purdue Pharma case decided by the Supreme Court on Thursday, in which the Sackler family, which owns the bankrupt opioid-maker, offered plaintiffs about $6 billion of the $11 billion they extracted from the company. In exchange, family members would have received immunity from future lawsuits, without filing for bankruptcy themselves. A 5-4 Supreme Court held that settlement was inadequate. Its ruling threw the massive bankruptcy case against Purdue Pharma into doubt after years of court battles over the company's role in the nation's opioid epidemic. The decision also adds a fresh wrinkle to a controversial legal strategy, called the Texas two-step, in which companies use a Texas law to split into separate companies and shift a large volume of legal claims onto the newly created entity. In the second step, the entity carrying the lawsuits files for bankruptcy and seeks to release its parent organization from all liability in exchange for a payout. Johnson & Johnson transferred some of its assets and all of the legal claims against it over asbestos-tainted talcum powder into a new legal entity that filed for Chapter 11. Boy Scouts of America ... agreed to pay $2.5 billion to settle claims of sexual abuse in bankruptcy court, a deal that shields from future litigation insurance companies as well as schools, churches and community organizations involved with the nonprofit.

Note: For more like this, read about how powerful corporations use the bankruptcy system to dodge lawsuits over sexual abuse and deadly products. Along US opioid industry lines, read how the industry operated like a drug cartel. Watch our Mindful News Brief video on how the deadly War on Drugs protects the activities of the rich and powerful: military-intelligence interests within the US government, big banks, Big Pharma, and drug cartels.

Americans are paying too much for prescription drugs. Pharmacy benefit managers ... are driving up drug costs for millions of people, employers and the government. The three largest pharmacy benefit managers, or P.B.M.s, act as middlemen overseeing prescriptions for more than 200 million Americans. They are owned by huge health care conglomerates – CVS Health, Cigna and UnitedHealth Group – and are hired by employers and governments. The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees. Most Americans get their health insurance through a government program like Medicare or through an employer, which pay for two different types of insurance for each person. One type covers visits to doctors and hospitals, and it is handled by an insurance company. The other pays for prescriptions. That is overseen by a P.B.M. The P.B.M. negotiates with drug companies, pays pharmacies and helps decide which drugs patients can get at what price. In theory, everyone saves money. But those savings appear to be largely a mirage, a product of a system where prices have been artificially inflated so that major P.B.M.s and drug companies can boost their profits while taking credit for reducing prices.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The pharma firms behind blockbuster weight loss drugs could face up to 10,000 lawsuits from patients who claim the drugs caused debilitating side effects like stomach paralysis and 'tearing holes' in the food pipe. Ozempic and sister shots like Wegovy and Mounjaro have recently come under fire over claims that the injections cause a roster of complications patients were allegedly not warned about. One woman told DailyMail.com that she suffered life-threatening stomach paralysis after taking Mounjaro, and has now joined a massive lawsuit against its maker Eli Lilly and Ozempic manufacturer Novo Nordisk. She claims she may never eat a solid meal again. Another said Ozempic caused so much internal damage she had to have her gallbladder removed, while another said the drug induced such violent vomiting it tore a hole in her esophagus. Now, Robert Peirce & Associates, a law firm based in Pittsburgh, estimates that the number of plaintiffs could explode to as many as 10,000. In addition to lawsuits, some patients have also claimed the drugs caused suicidal thoughts, psychosis, and appearance issues like deflated breasts. 'Unfortunately, the manufacturers of Ozempic and other GLP-1 agonists failed to adequately warn of the associated risks,' the Robert Peirce & Associates team wrote. Attorney Ken Moll ... said it was 'unconscionable' that the firms still hadn't added warnings to their labels which warn about the risk of gastroparesis and stomach paralysis.

Note: It is now estimated that 1 in 8 adults in the US have taken Ozempic or another weight-loss drug. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

New data from the National Institutes of Health reveal the agency and its scientists collected $710 million in royalties during the pandemic, from late 2021 through 2023. These are payments made by private companies, like pharmaceuticals, to license medical innovations from government scientists. Almost all that cash – $690 million – went to the National Institute of Allergy and Infectious Diseases, the subagency led by Dr. Anthony Fauci, and 260 of its scientists. Information about this vast private royalty complex is tightly held by the National Institutes of Health (NIH). My organization, OpenTheBooks.com, was forced to sue to uncover the royalties paid from September 2009 to October 2021, which amounted to $325 million over 56,000 transactions. Payments skyrocketed during the pandemic era: Those years saw more than double the amount of cash flow to NIH from the private sector, compared to the prior 12 combined. All told, it's $1.036 billion. NIH is still redacting pieces of the data that would help us more easily connect therapeutics with their government-paid inventors. For example, they refuse to show us the amount of royalties paid to each individual scientist. So we still can't entirely follow the money. In the meantime, Sen. Rand Paul (R-Ky.) has sponsored the Royalty Transparency Act, which sailed unanimously through the committee process and deserves a floor vote immediately.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry from reliable major media sources.

Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac. The lawsuits were filed in state courts across the country, but the agreements don't completely resolve Pfizer's exposure to the claims linking Zantac and cancer. Zantac was brought to market in 1983 by Glaxo Holdings, a company that is now part of the GlaxoSmithKline company. By 1988, it was the world's best selling drug as patients reported benefits for conditions such as heartburn, ulcers and acid reflux. In 2020, the Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in samples of the drug. Thousands of lawsuits began piling up in federal and state courts against Pfizer, GSK, Sanofi and Boehringer Ingelheim. Last month, Sanofi reached an agreement in principle to settle 4,000 lawsuits linking Zantac to cancer. Sanofi did not disclose the financial terms of the deal, but Bloomberg News reported that the company will pay $100 million – or $25,000 to each plaintiff. Sanofi still faces about 20,000 lawsuits over Zantac in Delaware state court. A judge in Delaware Superior Court in Wilmington is weighing the fate of about 70,000 cases filed against Sanofi and other defendants, including GSK, Pfizer and Boehringer Ingelheim.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Almost six in ten doctors in the US received more than $12 billion in payments from pharma firms in the past decade, an analysis has revealed. A study by researchers at Yale University found that 57 percent of doctors earned the huge sums from manufacturers in relation to medical drugs or devices between 2013 and 2022. Most of the money was for consulting services or fees for things such as serving as a speaker at a venue, but the physicians also received large amounts of money for food and beverages and gifts. Orthopedic surgeons were found to receive the largest total sum of payments, at $1.36bn, and the most common drugs related to payments were blood thinners Xarelto and Eliquis. 'Despite evidence that financial conflicts of interest may influence physician prescribing and may damage patients' trust in medical professionals, such payments remain pervasive,' the researchers wrote. After orthopedic surgeons, the physicians that received the largest total sum of payments were neurologists and psychiatrists, who received $1.32bn, and cardiologists, who got $1.29bn. Although the median payment to doctors was $48, payments to the top 0.1 percent of doctors were far higher and differed depending on specialty. The average amount paid to the top 0.1 percent of orthopedists was $4,826,944. For the top 0.1 percent of cardiologists, it was $3,197,675, and for the top 0.1 percent of neurologists and psychiatrists it was $2,588,819.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

What Americans eat, how they diet and exercise, what nutritional supplements they take, the sugar content of their sodas, the high fructose corn syrup in their processed foods, and the price of their diabetes medication have long been objects of endless gambling on Wall Street. Now, with drugs like Mounjaro, Wegovy, and Ozempic in the mix, new vistas of corporate exploitation have opened up. It's not a conspiracy theory that food addiction is a tool of corporate profiteering. Consider that tobacco companies, upon being regulated out of the business of addictive smoking, turned their sights onto addictive eating. Health columnist Anahad O'Connor wrote, "In America, the steepest increase in the prevalence of hyper-palatable foods occurred between 1988 and 2001–the era when Philip Morris and R.J. Reynolds owned the world's leading food companies." Many of these ultra-processed foods are specially marketed to children, which in turn can change their brain chemistry to desire those foods for life. Alongside the aggressive marketing of hyper-palatable foods is a massively profitable weight-loss industry that preys upon individual shame to the tune of more than $60 billion a year. In fact, some of the same companies pushing high-calorie foods are in the business of weight loss. The ultra-processed food industry is becoming symbiotic with the weight-loss drug industry. The former ensures we eat poorly and the latter is there to feed off our shame.

Note: This is strangely comparable to when pharmaceutical giant Purdue Pharma LP secretly pursued a plan to become "an end-to-end pain provider" by selling both opioids and drugs to treat opioid addiction. It is now estimated that 1 in 8 adults in the US have taken Ozempic or another weight-loss drug. For more along these lines, see concise summaries of deeply revealing news articles on food system corruption and Big Pharma profiteering from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.